Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study

• Published in: Dermatology and therapy Vol. 14; no. 12; pp. 3351 - 3366
• Main Authors: Gooderham, Melinda, Guttman-Yassky, Emma, Igawa, Ken, Kabashima, Kenji, Esfandiari, Ehsanollah, Rylands, Angela J., Williams, Angela, Nixon, Annabel, Dent, Jennifer E., Simpson, Eric
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.12.2024; Springer; Springer Nature B.V; Adis, Springer Healthcare
• Subjects: Adults; Atopic dermatitis; Biological products; Body mass index; Care and treatment; Clinical outcomes; Clinical trials; Demographics; Dermatitis; Dermatology; Dermatology Life Quality Index; Evaluation; Health-related quality of life (HRQL); Internal Medicine; Medical history; Medicine; Medicine & Public Health; Mental health; Methods; Missing data; Monoclonal antibodies; Oral and Maxillofacial Surgery; Original Research; Plastic Surgery; Pruritus; Quality of life; Quality of Life Research; Rocatinlimab; Skin diseases; Sleep; Sleep disturbance; Topical medication; Variance analysis; Canada; United States > US; Japan; Germany; Sleep disturbance; Pruritus; Atopic dermatitis; Dermatology Life Quality Index; Health-related quality of life (HRQL); Rocatinlimab

Introduction In adults with moderate-to-severe atopic dermatitis (AD), rocatinlimab demonstrated significant and progressive improvement in clinical measures of disease severity compared with placebo. This post hoc analysis of a phase 2b study was undertaken to understand the disease burden and to a...